RT CHARM: PHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION (ALLIANCE A221505)

Brief description of study

The primary rationale for accelerated PMRT is the enhanced convenience for patients, which may result in increased access to PMRT. With data now available documenting the low alpha/beta ratio for breast cancer, the fraction sensitivity of breast cancer can be exploited with higher fraction sizes, resulting in more compressed treatment times. We will deliver a dose of 42.56 Gy to the chest wall/reconstructed breast and regional nodes, in 16 daily fractions, 5 days a week. This fractionation should produce late effects and tumor control comparable to a conventionally fractionated course of 50 Gy to the chest wall and regional lymph nodes delivered in 2 Gy daily fractions


Clinical Study Identifier: s19-01594
ClinicalTrials.gov Identifier: NCT03414970
Principal Investigator: Naamit K. Gerber.


Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.